Bupa makes strong progress against its 3x100 strategy
Max Stanyard, Healthcare and Life Sciences Senior Analyst at RSM UK, comments on Bupa’s half year results: “Bupa's H1 results are a proof point for its 3x100 strategy: insurance customers are up 12% to 49.7m, revenue rose 10% to £9.9bn and underlying profit is up 21% to £594m. This reflects structural change, not favourable conditions alone. Rising consumer expectations, digital infrastructure and demographic growth are reshaping healthcare demand globally, from Türkiye and Spain to India, where these results show Bupa converting years of investment into financial momentum.
“Margin quality matters as much as growth here - the combined operating ratio improved to 94%, showing Bupa’s underwriting itself is getting more efficient, not just larger. That profitability is building up spare capital – Bupa is now holding significantly more capital than it needs even by its own internal safety targets, let alone regulatory minimums (Bupa's Solvency II coverage ratio now sits at 189%, comfortably above the top end of its own 140-170% working range).
“For a mutual with no shareholders to satisfy, that raises a genuine question: with capital already exceeding its target range, where does Bupa deploy it next? The Partnered Health acquisition in Australia signals appetite for further investment in health provision, but at this level of surplus, it’s reasonable to ask whether more may follow.”